BC Week In Review | Jul 5, 2010
Clinical News

Radiprodil: Preliminary Phase II data

Top-line data from a double-blind, placebo- and active-controlled, U.S. Phase II trial in 458 patients showed that radiprodil missed the primary endpoint of significantly reducing mean daily pain scores as measured by the 11-point Likert...
BioCentury | Jul 5, 2010

2Q approvals

2Q approvals Company Approvals Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Japan approves Soliris eculizumab to treat paroxysmal nocturnal hemoglobinuria (PNH) Amgen Inc. (NASDAQ:AMGN) FDA approves Prolia denosumab to treat osteoporosis in postmenopausal women whoare at high risk...
BC Extra | Jun 29, 2010
Clinical News

Radiprodil misses neuropathic pain endpoint

Forest Laboratories Inc. (NYSE:FRX) and Gedeon Richter Ltd. (Budapest:RICHTER) said late Monday that top-line data showed radiprodil ( RGH-896 ) missed the primary endpoint in a Phase II trial to treat neuropathic pain associated with diabetic peripheral...
BC Extra | Jan 18, 2006
Financial News

Forest misses Street

FRX reported third quarter fiscal 2006 EPS of $0.57, missing the Street estimate by $0.05 and down 19% from $0.70 in the same period last year. The EPS figure included a $0.05 per share payment...
Items per page:
1 - 4 of 4